308 related articles for article (PubMed ID: 29793956)
21. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.
Uchida H; Marzulli M; Nakano K; Goins WF; Chan J; Hong CS; Mazzacurati L; Yoo JY; Haseley A; Nakashima H; Baek H; Kwon H; Kumagai I; Kuroki M; Kaur B; Chiocca EA; Grandi P; Cohen JB; Glorioso JC
Mol Ther; 2013 Mar; 21(3):561-9. PubMed ID: 23070115
[TBL] [Abstract][Full Text] [Related]
22. Up to four distinct polypeptides are produced from the γ34.5 open reading frame of herpes simplex virus 2.
Korom M; Davis KL; Morrison LA
J Virol; 2014 Oct; 88(19):11284-96. PubMed ID: 25031346
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Saha D; Martuza RL; Rabkin SD
Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
[TBL] [Abstract][Full Text] [Related]
24. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
25. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract][Full Text] [Related]
27. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
[TBL] [Abstract][Full Text] [Related]
28. Δγ₁134.5 herpes simplex viruses encoding human cytomegalovirus IRS1 or TRS1 induce interferon regulatory factor 3 phosphorylation and an interferon-stimulated gene response.
Cassady KA; Saunders U; Shimamura M
J Virol; 2012 Jan; 86(1):610-4. PubMed ID: 22072777
[TBL] [Abstract][Full Text] [Related]
29. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
30. Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy.
Friedman GK; Raborn J; Kelly VM; Cassady KA; Markert JM; Gillespie GY
Front Oncol; 2013; 3():28. PubMed ID: 23450706
[TBL] [Abstract][Full Text] [Related]
31. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.
Friedman GK; Langford CP; Coleman JM; Cassady KA; Parker JN; Markert JM; Yancey Gillespie G
J Neurooncol; 2009 Nov; 95(2):199-209. PubMed ID: 19521665
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.
Ning J; Wakimoto H
Front Microbiol; 2014; 5():303. PubMed ID: 24999342
[TBL] [Abstract][Full Text] [Related]
33. Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells.
Liu X; He B
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404809
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia enhances the replication of oncolytic herpes simplex virus.
Aghi MK; Liu TC; Rabkin S; Martuza RL
Mol Ther; 2009 Jan; 17(1):51-6. PubMed ID: 18957963
[TBL] [Abstract][Full Text] [Related]
35. Multifunctional viral protein γ34.5 manipulates nucleolar protein NOP53 for optimal viral replication of HSV-1.
Meng W; Han SC; Li CC; Dong HJ; Wang XJ
Cell Death Dis; 2018 Jan; 9(2):103. PubMed ID: 29367603
[TBL] [Abstract][Full Text] [Related]
36. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
[TBL] [Abstract][Full Text] [Related]
37. Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors.
Hong B; Sahu U; Mullarkey MP; Kaur B
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062322
[TBL] [Abstract][Full Text] [Related]
38. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
[TBL] [Abstract][Full Text] [Related]
39. Enhanced antitumor efficacy of an oncolytic herpes simplex virus expressing an endostatin-angiostatin fusion gene in human glioblastoma stem cell xenografts.
Zhang G; Jin G; Nie X; Mi R; Zhu G; Jia W; Liu F
PLoS One; 2014; 9(4):e95872. PubMed ID: 24755877
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
Nakashima H; Kaufmann JK; Wang PY; Nguyen T; Speranza MC; Kasai K; Okemoto K; Otsuki A; Nakano I; Fernandez S; Goins WF; Grandi P; Glorioso JC; Lawler S; Cripe TP; Chiocca EA
J Clin Invest; 2015 Nov; 125(11):4269-80. PubMed ID: 26524593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
